Population Genomics of Plasmodium malariae from Four African Countries

Competing Interest Statement

JBP reports research support from Gilead Sciences, non-financial support from Abbott Laboratories, and consulting for Zymeron Corporation, all outside the scope of the current manuscript.

Funding Statement

This work was supported, in part, by the Bill & Melinda Gates Foundation [grant number 002202]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. Data collection in Geita, Tanzania was funded by USAID/PMI through Jhpiego and CDC. This study was funded in part by the National Institutes of Health (NIH) [T32AI007151 to Z.R.P-H.; T32AI070114 to R.S.; R01AI107949 and R01AI129812 to A.T.; R21 AI148579 to J.B.P. and J.T.L.; R01AI137395 and R21AI152260 to J. T. L.; R01AI132547 and K24AI134990 to J.J.J]. This work was supported through the DELTAS Africa initiative (DELGEME Grant 107740/Z/15/Z). The DELTAS Africa initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD) with funding from the Wellcome Trust (DELGEME Grant 107740/Z/15/Z) and the UK government.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

As part of the parent studies from which samples were derived, written informed consent, assent, and/or parental consent was obtained from all participants. Institutional review board approvals were obtained for parent studies as follows: Cameroon, from the Gambia Government/MRCG Joint Ethics Committee (REF SCC1626); DRC, from the University of North Carolina at Chapel Hill (IRB#: 14-0489) and the Kinshasa School of Public Health (ESP/CE/015/014); Nigeria, from the Cross River State Health Research Ethics Committee (REC No CRSMOH/RP/REC/2017/809). For the MSMT samples, the study protocol was submitted to the Tanzanian Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research (NIMR) for review and ethical approval and was approved. The protocol was also submitted for review and approval and approved by the ethics committee of WHO in Geneva, Switzerland. All research participants were asked and provided individual consent (or assent for children aged 7-17 years of age) for their participation in the survey and biobanking for future research. For children under the legal age of adulthood in Tanzania (< 18 years), consent was obtained from a parent or guardian. An informed consent form was developed in English and translated in Kiswahili and used to obtain consent both verbally and in writing from all participants. All participants agreed and signed the consent or assent form or provided a thumbprint in conjunction with the signature of an independent witness in case the study participant was illiterate. All experiments were performed in accordance with relevant guidelines and regulations in accordance with the Declaration of Helsinki. For the GANC samples, the study protocol was approved by the National Health Research Ethics Sub-Committee (NatHREC) of the Ministry of Health, Community Development, Gender, Elderly and Children (Dar es Salaam, Tanzania) and the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) institutional review board.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes